The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 342:1292-1293 April 27, 2000 Number 17
NextNext

Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Milgrom, H.
-PubMed Citation
To the Editor: Milgrom et al. (Dec. 23 issue)1 report on the treatment of allergic asthma with monoclonal IgE antibody. It has generally been accepted that IgE has a central role in the pathogenesis of anaphylaxis, allergic rhinitis, and asthma. However, several recent studies seem to question this concept.

Although the role of IgE has been best characterized in the pathogenesis of anaphylaxis and allergic rhinitis, acute anaphylaxis after allergen sensitization has been reported in the absence of IgE in laboratory animals.2 Casale et al.3 demonstrated that use of humanized anti-IgE monoclonal antibody in ragweed-sensitive patients with allergic rhinitis, both . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.